| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Many drugs used in clinical pharmacotherapy often induce serious injury of the lungs and sometimes result in lethal interstitial lung diseases. Though there is a great variation in the reported values about the prevalence of drug-induced lung diseases, it is high especially in the case of bleomycin. It is now recognized that epithelial-mesenchymal transition (EMT) plays an essential role in the fibrosis of various organs and is acknowledged to be one of the mechanisms underlying the generation of mesenchymal cells participating in tissue fibrosis.
In this study, we have found that RLE/Abca3 cells is a good in-vitro model to study drug-induced EMT, and TGF-β1 would be involved in the mechanism underlying bleomycin-induced EMT. In addition, quercetin, a flavonoid, may be a good therapeutic agent for drug-induced lung injury, which inhibits the intracellular ROS production and the TGF-β/smad pathway.
|
